MCAS supplements: evidence & limitations

Supplements for MCAS: what is established?

The most important framing first: no nutrient health claim authorised in the EU relates to MCAS. The studies cited here do not establish that a dietary supplement is effective in MCAS. What exists is decades of research on mast cells — and how that evidence is distributed across study levels is the real reason lists online differ so widely.

MCAS diagnostic criteria and their limitations →

Quercetin and luteolin: cell studies are not treatment evidence

The longest-running work concerns flavonoids. Kimata et al. (2000) sensitised cultured human mast cells with IgE and tested luteolin, baicalein and quercetin before anti-IgE challenge: all three inhibited release of histamine, leukotrienes, prostaglandin D2 and GM-CSF in a concentration-dependent manner, with luteolin and quercetin most strongly blocking calcium influx and protein kinase C signalling.

Kempuraj et al. (2005) compared several flavonols on human mast cells derived from cord blood: at 100 µM, quercetin or kaempferol lowered release of IL-6, IL-8 and TNF-α by 82–93 % and tryptase release by 79–96 %. The same group reported in 2006 that quercetin reduced tryptase and interleukin-6 release in HMC-1 cells and down-regulated histidine decarboxylase mRNA.

What matters in those figures is not the direction but the order of magnitude: 100 µM are concentrations that human blood does not normally reach after oral intake of a flavonoid. The studies describe what a compound can do to a mast cell if enough of it arrives — not what a capsule does in a person.

The head-to-head with a drug: Weng et al. (2012) compared quercetin with cromolyn and reported stronger inhibition of cytokine release from human mast cells by quercetin; the same work describes effects in contact dermatitis and photosensitivity. Tsilioni and Theoharides (2024) tested luteolin against cromolyn on the human mast cell line LADR — luteolin was significantly more potent at inhibiting release of histamine, tryptase, matrix metalloproteinase-9 and VEGF, and additionally inhibited IL-1β, IL-6, IL-8 and TNF, whereas cromolyn had no such effect.

Those authors state explicitly that a liposomal form is needed for orally taken luteolin to reach relevant ranges. That the relevant lever is structure rather than quantity was shown earlier by Weng et al. (2015): the structural analogue tetramethoxyluteolin inhibited histamine and β-hexosaminidase secretion in LAD2 cells more strongly than luteolin or cromolyn and suppressed NF-κB — in an animal model, not in humans.

Cell culture, observational study or controlled trial? →

Olive leaf and other dietary components: preclinical research

A wider view of dietary components: in a 2023 review, Kaag and Lorentz summarised that butyrate, calcitriol, kaempferol, quercetin, luteolin, resveratrol, curcumin and cinnamon extract most effectively suppressed mediator release from mast cells in cell and animal models. Randomised controlled trials exist for vitamin D, quercetin, O-methylated EGCG, resveratrol, curcumin and cinnamon extract — but in allergic rhinitis, not in MCAS. The authors themselves name poor bioavailability as the central research question.

Olive leaf has moved into focus more recently: Somma et al. (2025) treated human HMC-1.2 mast cells with olive leaf extract and observed reduced release of histamine and β-hexosaminidase plus lower expression and secretion of TNF-α, IL-6 and IL-8; the effect was NF-κB-dependent and accompanied by altered reactive-oxygen-species status and mitochondrial function. It is a cell study.

Vitamin C and histamine: oral is not intravenous

For vitamin C the evidence is older and split by route of administration. Clemetson (1980) analysed 437 human blood samples: once plasma ascorbate fell below 1 mg/100 ml, whole-blood histamine rose exponentially, and 1 g daily by mouth for three days lowered blood histamine in all eleven volunteers tested. Hagel et al. (2013) gave 7.5 g of ascorbic acid intravenously and observed serum histamine falling from 0.83 to 0.57 ng/ml per m² of body surface in 89 patients — more strongly in allergic than in infectious disease. Vollbracht et al. (2018) reported falling symptom scores under intravenous administration in an interim analysis of a multicentre observational study.

That distinction is decisive when comparing a capsule with a study: the clearest histamine reductions come from high-dose intravenous administration, a route that oral intake cannot be compared with. Oral data are small, old and partly tied to pregnancy or infection.

How DAO and HNMT break down histamine →

Assessing supplement research without promising effects

From this mix, four criteria let you assess a formulation without trusting promises: first, whether the compound is provided in a form for which human absorption data exist at all — for quercetin, phytosomes, whose plasma levels in a study by Riva et al. (2019) were many times above unformulated quercetin. Second, whether the study examines the same route of administration and population; cell-culture concentrations are not dosing advice. Third, whether composition and amounts are transparently declared. Fourth, whether possible interactions with medication have been discussed with a doctor.

A note on boundaries: mast cell activation is a mechanism, not a diagnosis. Anyone suspecting MCAS needs medical assessment against the consensus criteria — we have covered the diagnostic criteria and their limits separately. This article describes the research position on individual compounds only.

Calming mast cells: triggers, medical care and research limitations →